Literature DB >> 24941434

Hepatic dysfunction related to thyrotropin receptor antibody in patients with Graves' disease.

K He1, Y Hu1, X-H Xu1, X-M Mao1.   

Abstract

BACKGROUND: Hepatic dysfunction is a common phenomenon in patients with Graves' disease (GD). However, its pathogenesis is not fully understood. We aimed to determine the correlation between the thyrotropin receptor antibody (TRAb) and liver biochemical abnormalities in patients with GD.
METHODS: A total of 236 consecutive unrelated inpatients with newly diagnosed and untreated GD were included. Clinical characteristics (age, gender, disease duration) were collected. The liver biochemical values were tested and serum thyroid hormones, anti-thyroid antibodies and thyroid volumes were also evaluated. The patients were divided into hepatic dysfunction (HDF) and normal hepatic function (NHF) groups according to liver biochemical values.
RESULTS: We found that 77.9% untreated patients with GD had at least one liver function test abnormality. The levels of TRAb in patients of HDF group were significantly increased compared with those in patients of NHF group, P < 0.001. Linear regression suggested that TRAb has significant correlation with AST, ALP, γ-GTP, TB and DB. Logistic regression concluded that GD patients with high levels of TRAb had a greater possibility of developing liver biochemical abnormalities (OR = 1.069, 95% CI 1.019-1.113).
CONCLUSIONS: Hepatic dysfunction is common in patients with GD, and elevation of TRAb may contribute to hepatic dysfunction in patients with GD. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24941434     DOI: 10.1055/s-0034-1375667

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

1.  Incidence of abnormal liver biochemical tests in hyperthyroidism.

Authors:  Tiffany Y Lin; Anshula O Shekar; Ning Li; Michael W Yeh; Sammy Saab; Mark Wilson; Angela M Leung
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-09       Impact factor: 3.478

2.  RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease.

Authors:  Qing Zhang; Shaozheng Liu; Yanxing Guan; Qingjie Chen; Qing Zhang; Xiang Min
Journal:  J Clin Lab Anal       Date:  2017-05-31       Impact factor: 2.352

3.  Factors predicting abnormal liver function tests induced by Graves' disease alone: a retrospective cohort study.

Authors:  Ruiguo Zhang; Xun Tian; Lan Qin; Xiaoer Wei; Junqi Wang; Jie Shen
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

4.  Risk factors of hepatic dysfunction in patients with Graves' hyperthyroidism and the efficacy of 131iodine treatment.

Authors:  Renfei Wang; Jian Tan; Guizhi Zhang; Wei Zheng; Chengxia Li
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

5.  Liver enzyme profile and progression in association with thyroid autoimmunity in Graves' disease.

Authors:  Albert Hsieh; Stephen Adelstein; Susan V McLennan; Paul F Williams; Elizabeth L Chua; Stephen M Twigg
Journal:  Endocrinol Diabetes Metab       Date:  2019-07-15

Review 6.  Hyperthyroidism and Liver Dysfunction: A Review of a Common Comorbidity.

Authors:  Ernest Yorke
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2022-02-07

7.  Clinical-laboratory and ultrasound parallels of changes in the liver and thyroid gland in diffuse toxic goiter.

Authors:  Khrystyna Zynoviivna Lavruk; Petro Fedorovych Dudiy; Nadiya Vasylivna Skrypnyk; Vasyl Hryhorovych Mishchuk; Zynoviy Yaroslavovych Vytvytskiy
Journal:  J Med Life       Date:  2022-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.